GlaxoSmithKline Covid-19 drug falls short in trial, but may benefit older patients

An experimental rheumatoid arthritis drug being developed by GlaxoSmithKline failed to show a significant benefit in hospitalized patients with Covid-19, the drug maker said Thursday.

However, patients older than 70 were more likely to be free of respiratory failure, a result that GSK plans to test in a new cohort of the study.

“The bottom line is we’re doing a confirmatory cohort study,” said Mark Layton, a medical development lead at GSK. “We accept that subgroups can be misleading.”

Read the rest…

Read Original Article: GlaxoSmithKline Covid-19 drug falls short in trial, but may benefit older patients »